CLINICAL STUDIES


CLINICAL STUDIES

Farletuzumab  (MORAb-003)

Farletuzumab is an investigational monoclonal antibody that targets folate receptor alpha, a protein that is over-expressed on a number of cancers. It is currently being evaluated in clinical studies for the treatment of platinum-sensitive ovarian cancer and as a 1st line therapy for nonsmall cell lung cancer.

 

Amatuximab (MORAb-009)

Amatuximab is an investigational monoclonal antibody that targets mesothelin, a cell surface adhesion molecule that is over-expressed on a number of cancers. It is currently being evaluated in clinical studies as a 1st line therapy for mesothelioma.

 

Ontuxizumab (MORAb-004)

MORAb-004 is an investigational monoclonal antibody that targets endosialin, also known as tumor endothelial marker-1 (TEM1), or CD248, a protein that is over-expressed on blood vessels and fibroblasts associated with tumor stroma and on some malignant cells. It is currently being evaluated in clinical studies for the treatment of melanoma, chemorefractory metastatic colorectal cancer and sarcoma as well as in pediatric cancers.

 

MORAb-022

MORAb-022 is an investigational monoclonal antibody that targets a proinflammatory protein associated with autoimmune diseases. It is currently being evaluated in clinical studies for the treatment of rheumatoid arthritis.

 


MORAb-066

MORAb-066 is an investigational monoclonal antibody that targets tissue factor.  It is currently being evaluated in clinical studies for the treatment of pancreatic, breast, colorectal and non small cell lung cancer.



The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.